EphA2-targeted therapy strikes directly at cells of ovarian cancer
September 21, 2009
M.D. Anderson Cancer Center scientists have targeted a protein that is overexpressed in ovarian cancer cells and used it as a molecular homing mechanism to deliver chemotherapy in preclinical models. The protein, EphA2, is attractive for molecularly targeted therapy because its overexpression is associated with poor prognosis, according to Anil K. Sood, MD, and colleagues.